MX376056B - Pirimidinonas como inhibidores del factor xia. - Google Patents

Pirimidinonas como inhibidores del factor xia.

Info

Publication number
MX376056B
MX376056B MX2017003695A MX2017003695A MX376056B MX 376056 B MX376056 B MX 376056B MX 2017003695 A MX2017003695 A MX 2017003695A MX 2017003695 A MX2017003695 A MX 2017003695A MX 376056 B MX376056 B MX 376056B
Authority
MX
Mexico
Prior art keywords
inhibitors
factor xia
compounds
pyrimidinones
fxia
Prior art date
Application number
MX2017003695A
Other languages
English (en)
Spanish (es)
Other versions
MX2017003695A (es
Inventor
Andrew K Dilger
Donald J P Pinto
Lucca Indawati De
James R Corte
Kumar Balashanmuga Pabbisetty
Ii Leon M Smith
Michael J Orwat
Ruth R Wexler
Tianan Fang
William R Ewing
Wu Yang
Yeheng Zhu
Yufeng Wang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2017003695A publication Critical patent/MX2017003695A/es
Publication of MX376056B publication Critical patent/MX376056B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2017003695A 2014-10-01 2015-07-29 Pirimidinonas como inhibidores del factor xia. MX376056B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462058316P 2014-10-01 2014-10-01
PCT/US2015/042576 WO2016053455A1 (en) 2014-10-01 2015-07-29 Pyrimidinones as factor xia inhibitors

Publications (2)

Publication Number Publication Date
MX2017003695A MX2017003695A (es) 2017-05-30
MX376056B true MX376056B (es) 2025-03-07

Family

ID=53784023

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017003695A MX376056B (es) 2014-10-01 2015-07-29 Pirimidinonas como inhibidores del factor xia.
MX2020010840A MX2020010840A (es) 2014-10-01 2017-03-21 Pirimidinonas como inhibidores del factor xia.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020010840A MX2020010840A (es) 2014-10-01 2017-03-21 Pirimidinonas como inhibidores del factor xia.

Country Status (34)

Country Link
EP (4) EP3089979B1 (enExample)
JP (4) JP6462865B2 (enExample)
KR (2) KR101921436B1 (enExample)
CN (3) CN114957255A (enExample)
AR (1) AR101367A1 (enExample)
AU (3) AU2015324530B2 (enExample)
CA (1) CA2963395C (enExample)
CL (1) CL2017000712A1 (enExample)
CO (1) CO2017003833A2 (enExample)
CY (2) CY1119678T1 (enExample)
DK (2) DK3089979T3 (enExample)
EA (1) EA031590B1 (enExample)
ES (3) ES2655884T3 (enExample)
HR (2) HRP20171950T1 (enExample)
HU (2) HUE038061T2 (enExample)
IL (2) IL251434B (enExample)
LT (2) LT3293186T (enExample)
MA (1) MA40123A1 (enExample)
MX (2) MX376056B (enExample)
MY (2) MY201397A (enExample)
NO (1) NO2721243T3 (enExample)
PE (2) PE20210922A1 (enExample)
PH (2) PH12017500580B1 (enExample)
PL (1) PL3089979T3 (enExample)
PT (2) PT3293186T (enExample)
RS (2) RS56786B1 (enExample)
SG (2) SG10201911652TA (enExample)
SI (2) SI3293186T1 (enExample)
SM (2) SMT202000667T1 (enExample)
TN (2) TN2018000229A1 (enExample)
TW (3) TWI834182B (enExample)
UY (1) UY36244A (enExample)
WO (1) WO2016053455A1 (enExample)
ZA (1) ZA201702478B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
NO2760821T3 (enExample) 2014-01-31 2018-03-10
UY35971A (es) * 2014-01-31 2015-07-31 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Macrociclos con grupos p2? aromáticos como inhibidores del factor xia
CN107074821B (zh) 2014-09-04 2020-05-22 百时美施贵宝公司 为fxia抑制剂的二酰胺大环化合物
NO2721243T3 (enExample) * 2014-10-01 2018-10-20
CN107001391B (zh) 2014-10-01 2020-11-27 默克专利股份公司 硼酸衍生物
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CN108026083B (zh) 2015-06-19 2021-08-27 百时美施贵宝公司 作为因子xia抑制剂的二酰胺大环
JP6629958B2 (ja) * 2015-07-29 2020-01-15 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ アルキルまたはシクロアルキルＰ２’基を担持する大員環の第ＸＩａ因子阻害剤
EP3868753B1 (en) 2015-07-29 2022-12-21 Bristol-Myers Squibb Company Factor xia macrocyclic inhibitors bearing a non-aromatic p2' group
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
US10752641B2 (en) 2016-03-02 2020-08-25 Bristol-Myers Squibb Company Diamide macrocycles having factor XIa inhibiting activity
CA3013407A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
HUE054936T2 (hu) 2016-03-31 2021-10-28 Janssen Pharmaceuticals Inc Helyettesített indol-származékok mint a dengue-vírus replikációjának inhibitorai
EP3436004B1 (en) 2016-04-01 2024-12-11 Janssen Pharmaceuticals, Inc. Substituted indole compound derivatives as dengue viral replication inhibitors
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
WO2018133793A1 (zh) * 2017-01-18 2018-07-26 广东东阳光药业有限公司 凝血因子XIa抑制剂及其用途
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EA039702B1 (ru) 2017-05-22 2022-03-01 Янссен Фармасьютикалз, Инк. Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
EA201992782A1 (ru) 2017-05-22 2020-03-24 Янссен Фармасьютикалз, Инк. Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
EP3953334B1 (en) 2019-04-11 2023-11-22 Bristol-Myers Squibb Company Novel synthetic options towards the manufacture of (6r,10s)-10- {4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)- pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15 -(metheno)pyrazolo [4,3-b] [1,7] diazacyclotetradecin-5(6h)-one
EA202192753A1 (ru) * 2019-04-11 2022-01-11 Бристол-Маерс Сквибб Компани Повышенная эффективность аморфных твердых и солюбилизированных составов для достижения терапевтических концентраций в плазме
AU2020257911B2 (en) * 2019-04-16 2023-01-05 China Resources Biopharmaceutical Company Limited Macrocyclic derivatives acting as XIa factor inhibitor
US20220281868A1 (en) * 2019-07-23 2022-09-08 Medshine Discovery Inc. Macrocyclic derivatives as factor xia inhibitors
EP4036087A4 (en) * 2019-09-27 2023-09-20 Shenzhen Salubris Pharmaceuticals Co. Ltd Fxia inhibitors and preparation method therefor and pharmaceutical use thereof
IL297206A (en) * 2020-04-10 2022-12-01 Bristol Myers Squibb Co Crystalline forms of (9r, 135s)-13- {4-[5-chloro-2-(4-chloro-1h,2,3- triazol- 1 -yl)phenyl] -6-oxo- 1,6-dihydropyrimidin- 1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15- tetraazatricyclo [ 12.3.1.02·6] octadeca- 1(18), 2(6), 4, 14, 16-pentaen-8-one
TW202229280A (zh) * 2020-10-12 2022-08-01 美商必治妥美雅史谷比公司 （６ｒ，１０ｓ）－１０－｛４－［５－氯－２－（４－氯－１ｈ－１，２，３－三唑－１－基）苯基］－６－側氧基－１（６ｈ）－嘧啶基｝－１－（二氟甲基）－６－甲基－１，４，７，８，９，１０－六氫－１１，１５－（亞甲橋基）吡唑并［４，３－ｂ］［１，７］二氮雜環十四炔－５（６ｈ）－酮之製備方法
EP4274854A4 (en) 2021-01-08 2025-03-26 Bristol-Myers Squibb Company Antibodies and antigen binding peptides for factor xia inhibitors and uses thereof
TWI877478B (zh) * 2021-04-21 2025-03-21 大陸商上海美悦生物科技發展有限公司 FXIa抑制劑及其藥物組合物、製備方法和用途
CN119894901A (zh) * 2023-06-30 2025-04-25 深圳信立泰药业股份有限公司 一种多取代的大环化合物及其制备方法与应用
WO2025099743A1 (en) * 2023-11-07 2025-05-15 Dr. Reddy’S Laboratories Limited Process for preparation of milvexian and solid-state forms thereof
WO2025224678A1 (en) 2024-04-25 2025-10-30 Assia Chemical Industries Ltd. Solid state forms of milvexian and process for preparation thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3065190D1 (en) 1979-11-05 1983-11-10 Beecham Group Plc Enzyme derivatives, and their preparation
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
AU5546000A (en) 1999-06-14 2001-01-02 Protherics Molecular Design Limited Compounds
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
HRP20080382A2 (en) 2001-09-21 2008-12-31 Bristol-Myers Squibb Company A Delaware (Usa) Corporation LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR Xa INHIBITORS
US20040180855A1 (en) 2003-02-19 2004-09-16 Schumacher William A. Methods of treating thrombosis with reduced risk of increased bleeding times
KR101843542B1 (ko) * 2010-02-11 2018-03-30 브리스톨-마이어스 스큅 컴퍼니 인자 ＸＩａ 억제제로서의 마크로사이클
TW201311689A (zh) * 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之新穎巨環化合物
TW201319068A (zh) 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑
US9327839B2 (en) * 2011-08-05 2016-05-03 General Atomics Method and apparatus for inhibiting formation of and/or removing ice from aircraft components
ES2765891T3 (es) * 2011-12-21 2020-06-11 Ono Pharmaceutical Co Derivados de piridinona y pirimidinona como inhibidores del factor XIa
EA025392B1 (ru) * 2012-08-03 2016-12-30 Бристол-Маерс Сквибб Компани Дигидропиридон р1 в качестве ингибиторов фактора xia
BR112015002081A2 (pt) * 2012-08-03 2017-07-04 Bristol Myers Squibb Co di-hidropiridona p1 como inibidores de fator xia
NO2760821T3 (enExample) * 2014-01-31 2018-03-10
UY35971A (es) * 2014-01-31 2015-07-31 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Macrociclos con grupos p2? aromáticos como inhibidores del factor xia
NO2721243T3 (enExample) * 2014-10-01 2018-10-20

Also Published As

Publication number Publication date
AU2021245098A1 (en) 2021-10-28
TWI692478B (zh) 2020-05-01
RS61183B1 (sr) 2021-01-29
AU2021245098B2 (en) 2023-11-23
MY183987A (en) 2021-03-17
JP2019069989A (ja) 2019-05-09
ZA201702478B (en) 2019-06-26
AU2020200376B2 (en) 2021-07-08
CO2017003833A2 (es) 2017-07-11
EP3089979A1 (en) 2016-11-09
TW202310844A (zh) 2023-03-16
RS56786B1 (sr) 2018-04-30
JP6937734B2 (ja) 2021-09-22
TW201613923A (en) 2016-04-16
SMT202000667T1 (it) 2021-01-05
CL2017000712A1 (es) 2017-11-03
CA2963395C (en) 2023-03-14
CN110734435A (zh) 2020-01-31
SMT201800021T1 (it) 2018-03-08
NO2721243T3 (enExample) 2018-10-20
KR20170057431A (ko) 2017-05-24
PL3089979T3 (pl) 2018-02-28
TW202043228A (zh) 2020-12-01
TN2017000112A1 (en) 2018-07-04
AU2015324530A1 (en) 2017-05-18
KR101921436B1 (ko) 2018-11-22
MX2017003695A (es) 2017-05-30
WO2016053455A1 (en) 2016-04-07
IL251434A0 (en) 2017-05-29
MA40123A1 (fr) 2017-09-29
EP3828186B1 (en) 2023-08-23
EP3089979B1 (en) 2017-10-18
PH12017500580A1 (en) 2017-08-30
CN110734435B (zh) 2022-06-07
IL276470A (en) 2020-09-30
KR20180126612A (ko) 2018-11-27
KR102269999B1 (ko) 2021-06-25
AU2020200376A1 (en) 2020-02-06
PH12020500195A1 (en) 2021-02-08
CN114957255A (zh) 2022-08-30
EA031590B1 (ru) 2019-01-31
EP4286372A2 (en) 2023-12-06
BR112017006702A2 (pt) 2017-12-26
UY36244A (es) 2016-01-29
AU2015324530B2 (en) 2019-10-24
PE20210922A1 (es) 2021-05-19
TWI834182B (zh) 2024-03-01
SI3293186T1 (sl) 2021-01-29
ES2836270T3 (es) 2021-06-24
CY1119678T1 (el) 2018-04-04
EP3293186A1 (en) 2018-03-14
CN106795161A (zh) 2017-05-31
EP4286372A3 (en) 2024-02-21
TN2018000229A1 (en) 2019-10-04
HUE038061T2 (hu) 2018-09-28
JP2017530157A (ja) 2017-10-12
CA2963395A1 (en) 2016-04-07
HUE052812T2 (hu) 2021-05-28
EP3828186A3 (en) 2021-07-28
CN106795161B (zh) 2019-10-15
HRP20171950T1 (hr) 2018-02-23
ES2963267T3 (es) 2024-03-26
SG10201911652TA (en) 2020-02-27
HRP20201927T1 (hr) 2021-02-05
NZ766570A (en) 2024-01-26
CY1123663T1 (el) 2022-03-24
PE20170939A1 (es) 2017-07-13
EP3828186A2 (en) 2021-06-02
SI3089979T1 (sl) 2017-12-29
JP6462865B2 (ja) 2019-01-30
PT3089979T (pt) 2018-01-16
LT3089979T (lt) 2017-12-27
JP2023134734A (ja) 2023-09-27
TWI769442B (zh) 2022-07-01
DK3089979T3 (en) 2018-01-15
IL276470B (en) 2021-04-29
JP2021185182A (ja) 2021-12-09
JP7317905B2 (ja) 2023-07-31
SG11201702576QA (en) 2017-04-27
DK3293186T3 (da) 2020-12-14
EA201790595A1 (ru) 2017-07-31
NZ731416A (en) 2024-01-26
LT3293186T (lt) 2020-12-28
AR101367A1 (es) 2016-12-14
IL251434B (en) 2020-08-31
MX2020010840A (es) 2020-11-06
ES2655884T3 (es) 2018-02-22
MY201397A (en) 2024-02-21
PT3293186T (pt) 2020-12-09
EP3293186B1 (en) 2020-09-23
PH12017500580B1 (en) 2020-10-09

Similar Documents

Publication Publication Date Title
PH12020500195A1 (en) Pyrimidinones as factor xia inhibitors
PH12021550418A1 (en) Macrocycles with hetrocyclic p2` groups as factor xia inhibitors
MX2016009385A (es) Inhibidores macrociclicos del factor xia condensados con heterociclicos.
MX2015000919A (es) Dihidropiridona p1 como inhibidores del factor xia.
MX361759B (es) Compuestos macrocíclicos de dihidropiridona como inhibidores del factor xia y el uso de los mismos en el tratamiento de un trastorno tromboembólico.
MX376178B (es) Espirocicloheptanos como inhibidores de la cinasa rho (rock).
PH12015502248B1 (en) 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors

Legal Events

Date Code Title Description
FG Grant or registration